Mounjaro KwikPen 1 Pen 2.5 mg/0.6 ml

Mounjaro KwikPen 2.5 mg from Mounjaro (Eli Lilly) contains the active ingredient tirzepatide, which is an agonist of two receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Tirzepatide is a first-in-class dual receptor agonist developed to improve blood glucose control and support weight loss in patients. The drug is available as a prefilled injection pen (KwikPen).

Characteristics

• Active ingredient: Tirzepatide
• Manufacturer: Eli Lilly
• Release form: Injection solution in a pre-filled pen (KwikPen)
• Mechanism of action: Dual GLP-1 and GIP receptor agonist

Effects of using Mounjaro

In clinical studies, the use of Tirzepatide was associated with several positive metabolic changes:

1. significant reduction in glycated hemoglobin (HbA1c) levels.
2. improving glycemic control, reducing fasting and post-meal blood glucose levels.
3. weight loss due to decreased appetite and slower gastric emptying.
4. potential improvement in lipid profile parameters.

Medical indications for taking Mounjaro

Mounjaro is a prescription drug and is indicated for use only as directed by a physician. Key clinical indications include:

• Treatment of type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycemic control).
• Use in adult patients who require comprehensive management of blood sugar and weight.

Pharmacological action of Mounjaro

Mounjaro has a dual action by binding to both GLP-1 and GIP receptors:

• GLP-1 Agonism: Stimulates insulin secretion by pancreatic beta cells in response to food intake (glucose-dependent mechanism). It slows gastric emptying, reduces appetite, and decreases glucagon secretion.
• GIP Agonism: Enhances the effect of GLP-1, further stimulates insulin secretion and maintains a feeling of satiety.

This combination provides more effective and comprehensive control of glucose levels and energy balance than GLP-1 agonists alone.

How does Mounjaro work?

Tirzepatide mimics the action of two natural gut hormones. It increases cell sensitivity to insulin and increases insulin secretion only when blood sugar levels are high. The drug also reduces the amount of glucose produced by the liver and affects the appetite-control centers of the brain, leading to reduced food intake and subsequent weight loss.

Use and dosage of Mounjaro

All dosages, administration schedules, course duration, and frequency of use are indicated in the official instructions for the drug.

Before taking Mounjaro (or any other tirzepatide medication), be sure to consult with an endocrinologist or other qualified healthcare professional. Only a doctor can assess the appropriateness and safety of use, taking into account your health condition, concomitant medical conditions (especially diabetes, gastrointestinal diseases, thyroid, pancreatic, and gallbladder diseases), and medications you are taking.

Throughout the course, it is necessary to regularly undergo blood tests to monitor key indicators and promptly identify possible side effects.

Side effects

Because Mounjaro affects the gastrointestinal tract, the most common side effects are related to the digestive system. These are usually temporary and may include:

• Nausea, vomiting and diarrhea.
• Decreased appetite.
• Abdominal pain.

More serious but rare risks to be aware of include the potential for pancreatitis, severe allergic reactions, and the risk of hypoglycemia (especially when taken with other antidiabetic medications).

What to avoid

Mounjaro is contraindicated in cases of hypersensitivity to the active substance. The drug should not be used in patients with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2).

Avoid using Mounjaro in combination with other medications that affect glucose levels without strict medical supervision. Avoid increasing the dosage on your own.

Origin of the drug

Mounjaro (Tirzepatide) was developed and is manufactured by the American pharmaceutical company Eli Lilly and Company. It is a synthetic polypeptide created using recombinant DNA technology.